CEACAM5 Biological Pathways Reviews

Videos

Innovation and the Future Development of Cell Therapies for Patients With B-Cell Lymphomas

08/05/2024

At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.

At the 2024 Pan Pacific Lymphoma...

08/05/2024

Oncology

Videos

Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy

08/05/2024

Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.

Curtis Lachowiez, MD,...

08/05/2024

Oncology

Videos

Best Management Practices for a Patient With Early-Stage Non-Small Cell Lung Cancer

08/02/2024

Ticiana Leal, MD, discusses the course of treatment she would take for a patient with early-stage NSCLC.

Ticiana Leal, MD, discusses the...

08/02/2024

Oncology

Conference Coverage

Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases

08/02/2024

Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.

Rene Adam, MD, PhD, discusses...

08/02/2024

Oncology

Videos

Should Additional BCMA Therapy be Utilized After Prior BCMA Treatment for Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Should Stem Cell Transplantation be Suggested for Older Patients With Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Evaluating the Efficacy of R-Mini-CHOP With or Without Oral Azacytidine for Elderly Patients With DLBCL

07/29/2024

Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...

Elizabeth Brem, MD, shares...

07/29/2024

Oncology

Videos

CAR T-Cell Therapy vs Other Novel Therapies for Elderly Patients With Relapsed DLBCL

07/29/2024

At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.

At the 2024 Great Debates &...

07/29/2024

Oncology

Videos

Benefits of Utilizing CAR-T in Later Lines of Therapy for Patients With Multiple Myeloma

07/28/2024

At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.

At the 2024 Great Debates &...

07/28/2024

Oncology

Videos

Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?

07/28/2024

At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...

At the 2024 Great Debates &...

07/28/2024

Oncology

CEACAM5

ALIASES

Carcinoembryonic antigen-related cell adhesion molecule 5

References

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell surface glycoprotein that is a member of the carcinoembryonic antigen family, which contains 12 glycoproteins. It is used as a clinical biomarker for many different cancers. It may promote tumor development, metastasis, and cell adhesion by inhibiting differentiation and apoptosis, while disrupting tissue architecture through its role as a cell adhesion molecule.^1,2

Understanding the Role of CEACAM5

This animation explains the role of the CEACAM5 glycoprotein in the inhibition of cell differentiation and apoptosis, which can promote tumor growth and metastasis.

Expression in Cancer

Breast Cancer

50%

Colorectal Cancer

90%

Gastrointestinal Cancer

90%

Non-Small Cell Lung Cancer

70%

Pancreatic Cancer

90%

Prostate Cancer

60%

Resources

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology

Podcasts

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial

03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...

Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.

Petros Grivas, MD, PhD, shares...

03/07/2024

Oncology

Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA

Podcasts

Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer

02/16/2023

Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.

Sara Hurvitz, MD, shares how she...

02/16/2023

Oncology

Michael Hall, MD, Fox Chase Cancer Center

Podcasts

Advances in Genetic Testing for Patients With Gastrointestinal Cancers

12/20/2022

Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.

Michael Hall, MD, reviews his...

12/20/2022

Oncology

Podcasts

Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy

11/15/2022

Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.

Petros Grivas, MD, PhD, shares...

11/15/2022

Oncology

Podcasts

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma

07/29/2022

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Margherita Rimini, MD, discusses...

07/29/2022

Oncology

Ruth He, MD, Lombardi Comprehensive Cancer Center

Podcasts

Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

07/22/2022

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Ruth He, MD, discusses findings...

07/22/2022

Oncology

Arndt Vogel, MD, Hannover Medical School

Podcasts

Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

07/14/2022

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Arndt Vogel, MD, shares results...

07/14/2022

Oncology

Petros Grivas, MD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab Yields Encouraging Response Rates in Metastatic Urothelial Cancer

06/22/2022

Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Petros Grivas, MD, shares...

06/22/2022

Oncology

Podcasts

Maintenance Therapy With Cabozantinib Shows No Significant Benefit vs Placebo for Metastatic Urothelial Carcinoma

06/21/2022

Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.

Robert Jones, MD, shares results...

06/21/2022

Oncology

Podcasts

Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer

06/20/2022

In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.

In part 2 of this 2-part podcast...

06/20/2022

Oncology

Interactive

Quiz

Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

08/08/2024

Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?

Do you know whether maintenance...

08/08/2024

Oncology

Quiz

08/08/2024

Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...

Based on results from the phase...

08/08/2024

Oncology

Quiz

Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer

08/05/2024

True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...

True or False: According to...

08/05/2024

Oncology

Quiz

Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer

07/15/2024

According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?

According to the final analysis...

07/15/2024

Oncology

Quiz

Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma

07/12/2024

Oncology

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

Quiz

Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment

07/03/2024

Oncology

Quiz

FDA Approval of Lisocabtagene Maraleucel for MCL

07/01/2024

Oncology

Quiz

Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer

06/28/2024

True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).

True or False: As reported in...

06/28/2024

Oncology

Quiz

Treatment Options for a Patient With Early-Stage Non-Small Cell Lung Cancer

06/26/2024

What adjuvant treatment would you recommend?

What adjuvant treatment would...

06/26/2024

Oncology

Anti-CEACAM5 Antibodies

Therapies targeting CEACAM5 are currently in development for the treatment of multiple cancer types. This table outlines therapies in the pipeline.

View Table

Anti-CEACAM5 Antibodies in the Pipeline
Generic Drug Name	Potential Indications
Tusamitamab ravtansine^1-3	An antibody-drug conjugate targeting CEACAM5 being evaluated for the treatment of patients with non-small cell lung cancer, metastatic breast cancer, and metastatic pancreatic adenocarcinoma.

CEACAM5 Biological Pathways Reviews

Videos

CEACAM5

Understanding the Role of CEACAM5

Expression in Cancer

Resources

Podcasts

Interactive

Anti-CEACAM5 Antibodies

Specialties

Events

Year Round Education

HMP Global Products